147 related articles for article (PubMed ID: 18778761)
1. A novel liposomal formulation of flavopiridol.
Yang X; Zhao X; Phelps MA; Piao L; Rozewski DM; Liu Q; Lee LJ; Marcucci G; Grever MR; Byrd JC; Dalton JT; Lee RJ
Int J Pharm; 2009 Jan; 365(1-2):170-4. PubMed ID: 18778761
[TBL] [Abstract][Full Text] [Related]
2. Novel liposomal gefitinib (L-GEF) formulations.
Zhou X; Yung B; Huang Y; Li H; Hu X; Xiang G; Lee RJ
Anticancer Res; 2012 Jul; 32(7):2919-23. PubMed ID: 22753756
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
5. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
6. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of PEG-containing liposomal formulations on in vivo pharmacokinetics of streptokinase.
Jin SE; Kim IS; Kim CK
Arch Pharm Res; 2015 Oct; 38(10):1822-9. PubMed ID: 25851624
[TBL] [Abstract][Full Text] [Related]
8. Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin.
Wang T; Yin X; Lu Y; Shan W; Xiong S
Int J Nanomedicine; 2012; 7():2325-37. PubMed ID: 22661889
[TBL] [Abstract][Full Text] [Related]
9. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
10. The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate.
Zhang J; Chen Y; Li X; Liang X; Luo X
Int J Nanomedicine; 2016; 11():4187-97. PubMed ID: 27616886
[TBL] [Abstract][Full Text] [Related]
11. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
Shaji J; Menon I
Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
[TBL] [Abstract][Full Text] [Related]
12. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method.
Qiu L; Jing N; Jin Y
Int J Pharm; 2008 Sep; 361(1-2):56-63. PubMed ID: 18573626
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.
Chen KTJ; Militao GGC; Anantha M; Witzigmann D; Leung AWY; Bally MB
J Control Release; 2021 May; 333():246-257. PubMed ID: 33798663
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
Hong RL; Tseng YL
Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
[TBL] [Abstract][Full Text] [Related]
16. A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation.
Jiao YY; Wang XQ; Lu WL; Yang ZJ; Zhang Q
Eur J Pharm Sci; 2013 Jan; 48(1-2):249-58. PubMed ID: 23159667
[TBL] [Abstract][Full Text] [Related]
17. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
[TBL] [Abstract][Full Text] [Related]
18. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
19. Ammonium sulfate gradient loading of brucine into liposomes: effect of phospholipid composition on entrapment efficiency and physicochemical properties in vitro.
Chen J; Lin A; Chen Z; Wang W; Zhang T; Cai H; Cai B
Drug Dev Ind Pharm; 2010 Mar; 36(3):245-53. PubMed ID: 19678739
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
Zhai S; Sausville EA; Senderowicz AM; Ando Y; Headlee D; Messmann RA; Arbuck S; Murgo AJ; Melillo G; Fuse E; Figg WD
Anticancer Drugs; 2003 Feb; 14(2):125-35. PubMed ID: 12569299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
